• License provides Access to Genome Editing Platform
  • Eric Rhodes
  • Sunghwa Choe

News & Views

License provides Access to Genome Editing Platform

Mar 15 2021

G+FLAS Life Sciences, has been granted a non-exclusive license agreement to access to ERS Genomics’ CRISPR/Cas9 patent portfolio. The Korean biotech (Seoul) produces research tools and reagents under ISO 13485 and ISO 9001 and is applying CRISPR PLUS technology to the development of drugs and production of CRISPR genome edited plants in a non-GMO way.

ERS Genomics holds an exclusive worldwide license from co-founder and recent Nobel prize winner Dr. Emmanuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform.

“G+FLAS is developing genome editing applications using CRISPR/Cas9 that will further expand the reach of this important gene editing tool,” said Eric Rhodes, CEO of ERS Genomics. “We are pleased to provide access to this Nobel Prize winning technology and look forward to seeing G+FLAS continue in its mission.”

“We are very excited to sign this licensing agreement with ERS Genomics, to build on the strength of our existing platform and drive our future growth,” said Sunghwa Choe, CEO of G+FLAS Life Sciences. “Based on our advanced CRISPR PLUS research technology and global-standard production process, we will continue to innovate to meet our clients’ needs, to make differences in their discovery processes.”

Financial details of the agreement were not disclosed.

Digital Edition

ILM 49.5 July

July 2024

Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...

View all digital editions


ADLM 2024

Jul 28 2024 San Diego, CA USA

InaLab 2024

Jul 30 2024 Jakarta, Indonesia


Jul 31 2024 Chengdu, China

ACS National Meeting - Fall 2024

Aug 18 2024 Denver, CO, USA


Aug 25 2024 Copenhagen, Denmark

View all events